Ixekizumab

Ethan Craig, MD, spoke with Healio about treatment options currently available in psoriatic arthritis.

Patients with moderate to severe psoriasis in hard-to-treat areas of the body who received ixekizumab experienced long-term success over 5 years, according to a study.

Efficacy outcomes of ixekizumab through 12 weeks of treatment for psoriasis were consistent across multiple racial groups, although patient-reported outcomes were not, according to a study.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-17 inhibitor ixekizumab from the Maui Derm 2024 meeting.

SAN DIEGO — Biologic-naïve patients with radiographic axial spondylarthritis who receive ixekizumab for 16 weeks demonstrate reduced erosion scores and increased backfill scores, according to data presented at ACR Convergence 2023.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses the benefits of switching patients with psoriasis to risankizumab after suboptimal response from secukinumab or ixekizumab treatment.

An analysis of long-term ixekizumab use over 3 years in patients with axial spondyloarthritis found no new safety signals, according to data published in The Journal of Rheumatology.

As many as 96% of patients with axial spondyloarthritis who withdrew from ixekizumab after a favorable response were able to recapture low disease activity, while 71% retained inactive disease, after resuming the drug, according to data.

MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.